β-Hydroxybutyrate Alleviates Low Glucose-Induced Apoptosis via Modulation of ROS-Mediated p38 MAPK Signaling

Cixia Li1, Xuejun Chai2, Jiarong Pan1

  • 1College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China.

Insights

Beta-hydroxybutyrate (BHBA) protects against glucose deprivation-induced neuronal damage by reducing oxidative stress and apoptosis. BHBA activates ERK phosphorylation and inhibits p38 MAPK signaling, offering neuroprotection in low glucose conditions.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Hypoglycemia, a complication of diabetes treatment or negative energy balance, causes neuronal damage, cognitive impairment, and death due to oxidative stress and reactive oxygen species (ROS).
  • Beta-hydroxybutyrate (BHBA), a ketone body, serves as an alternative energy source and has shown potential in reducing apoptosis by inhibiting ROS and caspase-3 activation.

Purpose of the Study:

  • To investigate the effects of BHBA on apoptosis induced by glucose deprivation in neuronal cells.
  • To elucidate the molecular mechanisms underlying BHBA's neuroprotective effects in a glucose-deficient environment.

Main Methods:

  • Establishment of a low glucose injury model using PC12 cells and primary cortical neurons.
  • Treatment with varying concentrations of BHBA.
  • Assessment of cell survival, apoptosis rates, ROS production, neurite injury, and key protein expressions (p38, p-p38, NF-κB, caspase-3, p-ERK) using flow cytometry, immunofluorescence, and western blotting.

Main Results:

  • BHBA significantly inhibited ROS production and decreased apoptosis rates in PC12 cells and primary cortical neurons under low glucose conditions.
  • BHBA treatment increased cell survival rates and improved neurite integrity in primary cortical neurons.
  • BHBA modulated intracellular signaling pathways, decreasing p38 MAPK, NF-κB, and caspase-3 activity while increasing ERK phosphorylation.

Conclusions:

  • BHBA exerts neuroprotective effects against glucose deprivation by reducing oxidative stress and inhibiting apoptosis.
  • BHBA's mechanism involves mediating the p38 MAPK signaling pathway and caspase-3 cascade, alongside activating ERK phosphorylation.
  • These findings highlight BHBA's potential therapeutic role in managing hypoglycemia-induced brain injury.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
366
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
4.4K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
14.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
328
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
305